<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228692</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0686</org_study_id>
    <secondary_id>2019-A02583-54</secondary_id>
    <nct_id>NCT04228692</nct_id>
  </id_info>
  <brief_title>Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery</brief_title>
  <official_title>Evaluation of the Benefits of Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Symptomatic endometriosis can be responsible for urinary problems as well as symptoms of
      clinical bladder hyperactivity and/or symptoms of bladder pain before or during miction that
      can persist after bladder voiding. Whereas urinary problems can predate surgery due to the
      endometrial lesions themselves, the surgery can also have functional consequences for urinary
      function, specifically when there is trauma (incisions, per-operative coagulation) to the
      inferior hypogastric nerve fibers and/or to the hypogastric plexus.

      The incidence of post-surgery urinary symptoms could be as high as 30%. The incidence of
      voiding problems and specifically of non-obstructive voiding dysfunction can be observed in
      17,5% of cases of patients 1-month post-surgery for deep colorectal endometriosis, and
      persists in 4,8% of women after 12 months.

      The gold standard for treatment of voiding problems consists of self-catheterization, as is
      the case for all non-obstructive voiding dysfunction symptoms. This procedure considerably
      impacts quality of life. The proper and complete voiding of the bladder remains essential in
      order to avoid recurring urinary tract infections and pelvic static disorder.

      In the case of persistent dysuria, the use of self-catheterization is necessary in 21% of
      patients after surgery for deep endometriosis, for an average duration of 85 days. To date,
      few studies have explored the management of post-operative urinary complications after
      surgery for deep endometriosis. Pharmaceutical alternatives (alpha-blockers,
      anticholinergics, benzodiazepines) have not proven effective and sometimes cause side
      effects. However promising alternative treatments are being developed, specifically the
      neuromodulation of the sacral root. This procedure has been shown effective in the treatment
      of non-obstructive voiding dysfunction; however, it remains an invasive treatment that has
      its load of complications and undesirable side-effects. A recent study reports favorable
      results for the use of sacral neuromodulation in the case of persistent incomplete voiding
      following surgery for deep colorectal endometriosis. Some studies have also suggested that
      percutaneous posterior tibial nerve stimulation (PTN) could also be a treatment alternative.
      The advantage of this procedure is that it is non-invasive and less constraining. No study
      has yet evaluated whether PTN could also be used to treat patients with persistent voiding
      dysfunction following surgery for deep endometriosis.

      Our study, conducted in the gynecologic department of Croix ROUSSE Hospital, Lyon (France),
      evaluates PTN as a new treatment option for post-operative voiding dysfunction in women who
      suffer from deep endometriosis. Our aim is to prove that the use of PTN can reduce the
      duration of self-catheterization by 50% when compared to self-catheterization only.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of 50% of total duration of self-catheterization in the self-catheterization + PTN group</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Comparison of total numbers of days of self-catheterization between the 2 groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of self-catheterizations per day</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Patients will complete a voiding calendar as long as self-catheterization is required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post voiding residual urine volume (PVR)</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Patients will complete a voiding calendar as long as self-catheterization is required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of PVR&gt; 50% of spontaneous miction</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>Patients will complete a voiding calendar as long as self-catheterization is required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of PTN</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
    <description>sensation of small electrical discharges, skin reactions next to the electrodes will be notified by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of sessions of PTN per week</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of each session of PTN</measure>
    <time_frame>From the day of surgery to the end of self-catheterization or until a maximum of 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Endometriosis</condition>
  <condition>Dysuria</condition>
  <arm_group>
    <arm_group_label>Self-catheterization only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posterior tibial nerve stimulation + self-catheterization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients self-catheterized after each micturition, noting each volume of spontaneous micturition and each volume obtained by self-catheterization.
Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Self-catheterization only</intervention_name>
    <description>Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.</description>
    <arm_group_label>Self-catheterization only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Posterior tibial nerve stimulation + self-catheterization</intervention_name>
    <description>Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.</description>
    <arm_group_label>Posterior tibial nerve stimulation + self-catheterization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are eligible for the French public healthcare system

          -  Patients who have given their consent for this research

        Exclusion Criteria:

          -  Patients with cognitive, psychiatric or motor disturbances, that do not allow for
             independent use of the device

          -  Patients who do not speak French

          -  Patients who have had a surgery (bladder or ureters) for endometriosis or any other
             reason.

          -  Patients who were participating in another ongoing study, or within the exclusion time
             stipulated by another study (at the discretion of the investigator)

          -  Patients unable to give their consent (protected by law: under guardianship /
             trusteeship)

          -  Patients who are taking a pharmaceutical treatment for urological problem
             (anticholinergics, alpha-blockers, prostaglandin)

          -  Pregnant or breastfeeding women

          -  Patients with a pacemaker

          -  Patients with dermatological problem in the area where the device's electrodes have to
             be installed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie WAREMBOURG, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie WAREMBOURG, Dr</last_name>
    <phone>4.72.07.19.36</phone>
    <phone_ext>+33</phone_ext>
    <email>sophie.warembourg@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie WAREMBOURG, Dr</last_name>
      <phone>4.72.07.19.36</phone>
      <phone_ext>+33</phone_ext>
      <email>sophie.warembourg@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep endometriosis surgery</keyword>
  <keyword>voiding dysfunction</keyword>
  <keyword>self-catheterization</keyword>
  <keyword>posterior tibial nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Dysuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

